section name header

Indications

REMS


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

MS: arthralgia

Neuro: malaise

Misc: ANAPHYLAXISHYPERSENSITIVITY REACTIONS INCLUDING , neutralizing antibodies

Interactions

Drug-drug:

Availability

Route/Dosage

Control/prevention of bleeding episodes

Perioperative Management

Routine prophylaxis

US Brand Names

Eloctate

Action

  • Replaces deficient antihemophilic factor (AHF, Factor VIII). Produced via recombinant DNA technology, presence of fusion protein delays degradation.
Therapeutic effects:
  • Decreased incidence and severity of bleeding in patients with Hemophilia A.

Classifications

Therapeutic Classification: hemostatic agents

Pharmacologic Classification: clotting factors replacements

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-Life: Unknown; clearance is more rapid in children.

Time/Action Profile

(effects on hemostasis)

ROUTEONSETPEAKDURATION
IVrapidend of infusion6 hr-5 days

Depends on patient age and clinical situation.



Patient/Family Teaching

Pronunciation

an-teye-hee-moe-FEEL-ik FAK-tor ree-KOM-bi-nant eff-cee FYOO-zhun PROH-teen